Welcome to my homepage. I have a number of responsibilities within the School of Pharmacy and Medical Sciences. I am the Associate Head (Research) of the School, responsible for ensuring that all research conducted by its staff is of the highest quality. As part of this task, I am also the Research Degrees Co-ordinator for the School, responsible for overall management of the School's more than 130 postgraduate research students. I am a member of the Drug Discovery and Development group, which is within the School and the Sansom Institute located within the Division of Health Sciences. I am actively involved in a number of research projects with staff in the Institute and with colleagues attached to hospitals in Adelaide and interstate. I... Read more
With standout facilities and strong industry links, the School prepares students for careers in health and medical science.
Welcome to my homepage. I have a number of responsibilities within the School of Pharmacy and Medical Sciences. I am the Associate Head (Research) of the School, responsible for ensuring that all research conducted by its staff is of the highest quality. As part of this task, I am also the Research Degrees Co-ordinator for the School, responsible for overall management of the School's more than 130 postgraduate research students. I am a member of the Drug Discovery and Development group, which is within the School and the Sansom Institute located within the Division of Health Sciences. I am actively involved in a number of research projects with staff in the Institute and with colleagues attached to hospitals in Adelaide and interstate. I consult widely to the pharmaceutical and biotechnology industry on pre-clinical and clinical studies, and work closely with CPR Pharma, a spin-out company from UniSA. I have also provided scientific advice to patent firms on matters related to pharmaceutical science. I teach courses in Pharmaceutical Science/Dosage Form Design.
Doctor of Philosophy The University of Adelaide
Master of Science The University of Sydney
Bachelor of Pharmacy The University of Sydney
Excludes commercial-in-confidence projects.
The inhibition of Biotin Protein Ligase as a new source of antibiotics, NHMRC - Project Grant, 01/01/2014 - 30/08/2017
Training DFAT 2016, Department of Foreign Affairs and Trade, 01/08/2016 - 30/06/2017
New treatment for childhood leukaemia, Channel 7 Children's Research Foundation of SA, 01/01/2016 - 31/12/2016
Stability of liquid dosage forms of clopidgrel for paediatric use, Women's and Children's Hospital, 15/05/2014 - 30/12/2016
Beat Cancer Travel Grant 2016 (L Tan)011413, Cancer Council SA - Beat Cancer Travel Grant, 25/05/2016 - 30/12/2016
Determination of Neratinib from rat serum by liquid chromotography - tandem mass spectometry, Adelaide Research & Innovation Pty Ltd, 18/09/2015 - 29/09/2016
Determination of population rates of drug use through analysis of wastewater samples, Central Adelaide Local Health Network Incorporated, 01/10/2011 - 01/10/2015
Development of an anti-cancer mitotic inhibitor MKI-77, Cancer Council SA - Beat Cancer, 01/07/2012 - 31/08/2013
Open access indicates that an output is open access.
Li, P, Diab, S, Yu, M, Adams, J, Islam, S, Basnet, SK, Albrecht, H, Milne, RW & Wang, S 2016, 'Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells', Oncotarget, vol.7, no.35, pp.1-15.
Open access 1
Rahaman, MH, Kumarasiri, M, Mekonnen, LB, Yu, M, Diab, S, Albrecht, H, Milne, RW & Wang, S 2016, 'Targeting CDK9: a promising therapeutic opportunity in prostate cancer', Endocrine-Related Cancer, vol. 23, no. 12, pp. T211-T226.
2 1 2
Bai, PY, Wittert, GA, Taylor, AW, Martin, SA, Milne, RW & Shi, Z 2015, 'The association of socio-demographic status, lifestyle factors and dietary patterns with total urinary phthalates in Australian men', PLoS One, vol. 10, no. 4, article no. e0122140, pp. 1-13.
Open access 4 4 5
Le, BT, Kumarasiri, M, Adams, J, Yu, M, Milne, RW, Sykes, MJ & Wang, S 2015, 'Targeting Pim kinases for cancer treatment: Opportunities and challenges', Future Medicinal Chemistry, vol. 7, no. 1, pp. 35-53.
3 3 4
Al Haj Diab, S, Teo, THS, Kumarasiri, M, Li, P, Yu, M, Lam, FK, KC Basnet, S, Sykes, MJ, Albrecht, H, Milne, RW & Wang, S 2014, 'Discovery of 5-( 2-( Phenylamino) pyrimidin-4-yl) thiazol2( 3H)- one Derivatives as Potent Mnk2 Inhibitors: Synthesis, SAR Analysis and Biological Evaluation', ChemMedChem: chemistry enabling drug discovery, vol. 9, no. 5, pp. 962-972.
Open access 16 17 1
Open access 29 29 2
Grant, J, Martin, S, Taylor, A, Wilson, D, Araujo, A, Jenkins, A, Milne, RW, Hugo, G, Atlantis, E & Wittert, GA 2014, 'Cohort Profile: The Men Androgen Inflammation Lifestyle Environment and Stress (MAILES) Study', International Journal of Epidemiology, vol. 43, no. 4, pp. 1040-1053.
15 13 1
Licari, G, Somogyi, AA, Milne, RW & Sallustio, BC 2014, 'Comparison of CYP2D metabolism and hepatotoxicity of the myocardial metabolic agent perhexiline in Sprague-Dawley and Dark Agouti rats', Xenobiotica: the fate of foreign compounds in biological systems, vol. 45, no. 1, pp. 3-9.
Lu, T, Goh, AW, Yu, M, Adams, J, Lam, F, Teo, T, Li, P, Noll, B, Zhong, L, Diab, S, Chahrour, O, Hu, A, Abbas, AY, Liu, X, Huang, S, Sumby, CJ, Milne, R, Midgley, C & Wang, S 2014, 'Discovery of (E)-3-((styrylsulfonyl)methyl)pyridine and (E)-2-((styrylsulfonyl)methyl)pyridine derivatives as anticancer agents: synthesis, structure-activity relationships, and biological activities', Journal of Medicinal Chemistry, vol. 57, no. 6, pp. 2275-2291.
Open access 6 6
Open access 1
Death, C, Taggart, D, Williams, DB, Milne, RW & Schultz, D 2011, 'Pharmacokinetics of moxidectin in the southern hairy-nosed wombat (Lasiorhinus latifrons)', Journal of Wildlife Diseases, vol. 47, no. 3, pp. 643-649.
Wiese, MD, Davies, N, Chataway, T, Milne, RW, Brown, S & Heddle, R 2011, 'Stability of Myrmecia pilosula (Jack Jumper) Ant venom for use in immunotherapy', Journal of Pharmaceutical and Biomedical Analysis, vol. 54, no. 2, pp. 303-310.
4 4 3
Dudhani, R V, Turnidge, J, Coulthard, K, Milne, RW, Rayner, C, Li, J & Nation, R 2010, 'Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models', Antimicrobial Agents and Chemotherapy, vol. 54, no. 3, pp. 1117-1124.
Lickliter, J, Francesconi, A, Smith, G, Burge, M, Coulthard, A, Rose, S, Griffin, M, Milne, RW, McCarron, J, Yeadon, T, Wilks, A, Cubitta, A, Wyld, D & Vasey, P 2010, 'Phase i trial of CYT997, a novel cytotoxic and vascular-disrupting agent', British Journal of Cancer, vol. 103, no. 5, pp. 597-606.
Open access 17 14
15 11 1
Ma, Z, Wang, J, Nation, R, Li, J, Turnidge, J, Coulthard, K & Milne, RW 2009, 'Renal disposition of colistin in the isolated perfused rat kidney', Antimicrobial Agents and Chemotherapy, vol. 53, no. 7, pp. 2857-2864.
Turkanovic, J, Ngo, SN & Milne, RW 2009, 'Effect of St John's wort on the disposition of fexofenadine in the isolated perfused rat liver', Journal of Pharmacy and Pharmacology, vol. 61, no. 8, pp. 1037-1042.
Bergen, P, Li, J, Nation, R, Turnidge, J, Coulthard, K & Milne, RW 2008, 'Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model', Journal of Antimicrobial Chemotherapy, vol. 61, no. 3, pp. 636-642.
77 70 4
Davies, B, Herbert, M, Coller, J, Somogyi, A, Milne, RW & Sallustio, B 2008, 'Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline', British Journal of Clinical Pharmacology, vol. 65, no. 3, pp. 347-354.
Ma, Z, Wang, J, Gerber, JP & Milne, RW 2008, 'Determination of colistin in human plasma, urine and other biological samples using LC-MS/MS', Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 862, no. 1-2, pp. 205-212.
Wallace, S, Li, J, Nation, R, Rayner, C, Taylor, DK, Middleton, D, Milne, RW, Coulthard, K & Turnidge, J 2008, 'Subacute toxicity of colistin methanesulfonate in rats: Comparison of various intravenous dosage regimens', Antimicrobial Agents and Chemotherapy, vol. 52, no. 3, pp. 1159-1161.
Wiese, MD, Milne, RW, Davies, N, Chataway, T, Brown, S & Heddle, R 2008, 'Myrmecia pilosula (Jack Jumper) ant venom: Validation of a procedure to standardise an allergy vaccine', Journal of Pharmaceutical and Biomedical Analysis, vol. 46, no. 1, pp. 58-65.
7 7 3
|Charles Darwin University||AUSTRALIA|
|CSIRO Australia (Commonwealth Scientific Industrial Research Organisation)||AUSTRALIA|
|Cytopia Research Pty Ltd||AUSTRALIA|
|Flinders Medical Centre||AUSTRALIA|
|Monash Medical Centre||AUSTRALIA|
|Open University||UNITED KINGDOM|
|Queen Elizabeth Hospital||AUSTRALIA|
|Queensland Institute of Medical Research||AUSTRALIA|
|Royal Brisbane and Women's Hospital||AUSTRALIA|
|Royal Zoological Society of SA||AUSTRALIA|
|University of Adelaide||AUSTRALIA|
|University of Melbourne||AUSTRALIA|
|University of Nottingham||UNITED KINGDOM|
|University of Queensland||AUSTRALIA|
|University of South Australia||AUSTRALIA|
|University of Southampton||UNITED KINGDOM|
|University of Sydney||AUSTRALIA|
|University of Tasmania||AUSTRALIA|
|University of Texas Southwestern Medical Center||UNITED STATES|
|University of Western Australia||AUSTRALIA|
|Women's and Children's Hospital||AUSTRALIA|
Supervisions from 2010 shown
|Thesis title||Student status|
|Evaluation of CDK4/6 inhibitors for treatment of cancer||Current|
|Novel methods of analysis and pharmacokinetics of viper venom components in human plasma||Current|
|Pharmacodynamic evaluation of CDK9 inhibitors in the treatment of cancer||Current|
|Pharmacological evaluation of cdk inhibitors for treatment of cancer||Current|
|Pharmalogical evaluation of protein kinase inhibitors||Current|
|Targeting Cyclin-dependent kinases 4/6 for treatment of cancer||Current|
|Developing inhibitorsof MAP kinase-interacting kinases as potential anti-cancer agents||Completed|
|Discovery and evaluation of MNK inhibitors as potential anti-cancer agents||Completed|
|Effect of garlic and ginkgo extracts on the pharmacokinetics of fexofenadine: a mechanistic study||Completed|
|Pharmacokinetic interaction between morphine and ketamine||Completed|
|Renal disposition of colistin and colistin methanesulfonate in the isolated perfused rat kidney||Completed|
|The impact of formulating 5-Fluorouracil into liposomes on its site-specific delivery to tumour tissue||Completed|